Role of interferon-α and clonally expanded T cells in the immunotherapy of chronic myelogenous leukemia

Leukemia and Lymphoma

Volumn 38, Issue 1-2, 2000, Pages 21-38

  Fujii, Shin Ichiro ^a  

^a NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; HUMAN; LYMPHOCYTE CLONE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE STRAND CONFORMATION POLYMORPHISM; T LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE;

EID: 0010686026     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009060316     Document Type: Review

References (138)

1. Hasford, J., Pfirrmann, M., Hehlmann, R., Allan, N.C., Baccarani, M., Kluin-Nelemans, J.C., Alimena, G., Steegmann, J.L. & Ansari, H. (1998) A new prognostic score for patients with chronic myeloid leukemia treated with interferon alpha. J Natl Cancer Inst, 90, 850-858.
2. Ling, P.D., Warren, M.K. & Vogal, S.N. (1985) Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages. J Immunol. 135, 1857-1863.
3. Siegal, F.P., Kadowaki, N., Shodell, M., Fitzgerald-Bacarsly, P.A., Shah, K., Ho, S., Antonenko, S., & Liu, Y.J. (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science, 284, 1835-1837.
4. Cella, M., Jarrossay, D., Facchetti, F., Alebardi, O., Nakajima, H., Lavanzecchia A. & Colonna, M. (1999) Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type 1 interferon. Nat Med, 8, 919-923.
5. Ghanekar, S., Zheng, L., Logar, A., Navratil, J., Borowski, L., Gupta, P. & Rinaldo, C. (1996) Cytokine expression by human peripheral blood dendritic cells stimulated in vitro with HIV-1 and herpes simplex virus. J Immunol, 157, 4028-4036.
6. Tough, D.F., Borrow, P. & Sprent, J. (1996) Induction of bystander T cell proliferation by viruses and type 1 interferon in vivo. Science, 272, 1947-1950.
7. Marmont, A., Horowitz, M., Gale, R., Sobocinski, K., Ash, R., van Bekkum, D., Champlin, R., Dicke, K., Goldman, J., Good, R., Herzig, R., Hong, R., Masaoka, T., Rimm, A., Ringden, O., Speck, B., Weiner, R. & Borti, M. (1991) T cell depletion of HLA identical transplants in leukemia. Blood, 78, 2120-2130.
8. Kolb, H.J., Mittermuller, j., Clemm, C., Holler, E., Ledderrose, G., Brehm, G., Heim, M. & Wilmanns, W. (1992) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76, 2462-2565.
9. + progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci USA, 95, 10152-10157.
10. Coleman, S., Fisher, J., Hoy, T., Burnett, A.K. & Lim, S.H. (1996) Autologous MHC-dependent leukaemia-reactive T lymphocytes in a patient with chronic myeloid leukaemia. Leukemia, 10, 483-487.
11. Legha, S.S. (1997) The role of interferon-alpha in the treatment of metastatic melanoma. Semin Oncol, 24, 1 Suppl. 4, S24-31.
12. Weinstock-Guttman, B., Ransohoff, R.M., Kinkel, R.P. & Rudick, R.A. (1995) The interferons: biological effects, mechanisms of action, and use in multiple sclerosis [Review]. Ann. Neurol., 37, 7-15.
13. Ellis, T.M., McKenzie, R.S., Simms, P.E., Helfrich, B.A. & Fisher, R.I. (1989) Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. J Immunol, 143, 4282-4286.
14. Meseri, A., Delwail, V., Brizard, A., Lecron, J.C., Pelletier, D., Guilhot, F., Tanzer, J. & Goube de Laforest, P. (1993) Endogenous lymphokine activated killer cell activity and cytogenetic response in chronic myelogenous leukaemia treated with alpha-interferon. Br J Haematol, 83, 218-222.
15. Schmidt, H., Kellermann-Kegreiss, E., Steiert, I., Walz, J., Zinser, R. & Muller, C.A. (1993) Differential regulation of human leukocyte antigen class I genes by interferon in vivo and in vitro. J Immunother, 14, 169-174.
16. Gutterman, J.U. (1994) Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA, 91, 1198-1205.
17. Romagnani, S. (1992). Induction of TH1 and TH2 responses: a key role for the "natural" immune response? Immunology Today, 13, 379-81.
18. Biron, C.A. (1997) Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol, 9, 24-34.
19. Wenner, C.A.M., Guler, L., Macatonia, S.E., O'Garra, A. & Murphy, K.M. (1996) Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol, 156, 1442-1447.
20. McRae, B.L., Semnani, T., Hayes, M.P. & van Seventer, G.A. (1998) The type 1 IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J Immunol, 160, 4298-4304.
21. Marrack, P., Kappler, J. & Mitchell, T. (1999) Type 1 interferons keep activated cells alive. J Exp Med, 189, 521-529.
22. Haque, S.J. & Williams, B.R. (1998) Signal transduction in the interferon system [Review]. Semin Oncol, 25, 14-22.
23. Cho, S.S., Bacon, C.M., Sudarshan, C., Rees, R.C., Finbloom, D., Pine, R. & O'Shea, J.J. (1996) Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol, 154, 4781-4789.
24. + helper T cells. A model for the long term survival of memory cells. J Immunol, 156, 1764-1777.
25. The Italian Cooperative Study Group on chronic myeloid leukemia. (1994) Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med, 330, 820-825.
26. Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H.J., Pralle, H., Hossfeld, D.K., Quisser, W., Loffler, H., Hochhaus, A., Heinze, B., Georgii, A., Bartram, C.R., Griesshammer, M., Bergmann, H., Walther, F., Fett, W., Kleeberg, U.R. & Kabisch, A. (1994) Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood, 84, 4064-4077.
27. Ohnishi, K., Ohno, R., Tomonaga, M., Kamada, N., Onozawa, K., Kuramoto, A., Dohy, H., Mizoguchi, H., Miyawaki, S., Tsubaki, K., Miura, Y., Omine, M., Kobayashi, T., Naoe, T., Ohshima, T., Hirashima, K., Ohtake, S., Takahashi, I., Morishima, K., Naito, K., Asou, N., Tanimoto, M., Sakuma, A. & Yamada, K. (1995) A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood, 86, 906-916.
28. Silver, R.T., Woolf, S.H., Hehlmann, R., Appelbaum, F.R., Anderson, J., Bennett, C., Goldman, J.M., Guihot, F., Kantarjian, H.M., Lichtin, A.E., Talpaz, M. & Tura, S. (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the american society of hematology. Blood, 94, 1517-1536.
29. Sawyers, C. (1999) Chronic myeloid leukemia. N Engl J Med, 340, 1330-1339.
30. Kantarjian, H.M., Talpaz, M., O'brien, S., Kurzrock, R., Gutterman, J., Keating, M.J., McCredie, K.B. & Freireich, E.J. (1997) Chronic myelogenous leukemia-progress at the M.D. Anderson Cancer Center over the past two decades and future direction: First Emil Freireich Award Lecture. Clin Cancer Res, 3, 2723-2733.
31. Faderl, S., Talpaz, M., Estov, Z. & Kantarjian, H.M. (1999) Chronic myelogenous leukemia: biology and therapy. Ann Intern Med, 131, 207-219.
32. Allan, N.C., Richards, S.M. & Shepherd, P.C.A. on behalf of the UA Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukemia. (1995) Results of the Medical Research Council randomized multi-centre trial of interferon-anl for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet, 345, 1392-1397.
33. Cortes, J., Talpaz, M., O'brien, S., Rios, M.B., Majlis, A., Keating, M., Freireich, E.J. & Kantarjian, H. (1998) Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol, 16, 3279-3285.
34. Kurzrock, R., Shaltrid, M., Talpaz, M., Kloetzer, W.S. & Gutterman, J.U. (1987) Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. Blood, 70, 1584-1588.
35. Chronic Myeloid Leukemia Trialists Collaborative Group. (1997) Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst, 89, 1616-1620.
36. Yee, K., Anglin, P. & Keating, A. (1999) Molecular approaches to the detection and monitoring of chronic myeloid leukemia: therapy and practice. Blood Reviews, 13, 105-126.
37. Kantarjian, H.M., Smith, T.L., O'Brien, S., Beran, M., Pierce, S. & Talpaz, M. (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med. 122, 254-261.
38. Sacchi, S., Kantarjian, H., O'Brien, S., Cohen, P.R., Pierce, S. & Talpaz, M. (1995) Immune-mediated and unusal complications during interferon alpha therapy in chronic myelogenous leukemia. J Clin Oncol, 13, 2401-2407.
39. Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R. & Kantarjian, H.M. (1999) The biology of chronic myeloid leukemia. N Engl J Med, 341, 164-172.
40. Hochhaus, A., Reiter, A., Skladny, H., Reichert, A., Saussele, S. & Hehlmann, R. (1998) Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy. Rec Res Cancer Res, 144, 36-45.
41. Muhlmann, J., Thaler, J., Hilbe, W., Bechter, O., Erdel, M., Utermann, G. & Duba, H.C. (1998) Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Gene Chromosomes Cancer, 21, 90-100.
42. Dewald, G.W., Wyatt, W.A., Juneau, A.L., Carlson, R.O., Zinsmeister, A.R. Jalal, S.M., Spurbeck, J.L. & Silver, R.T. (1998) Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood, 91, 3357-3365.
43. Buno, I., Wyatt, W.A., Zinsmeister, A.R., Dietz-Band, J., Silver, R.T. & Dewald, G.W. (1998) A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood, 92, 2315-21.
44. Lee, M., Kantarjian, H. & Talpaz, M. (1942) Association of the responsiveness to interferon (IFN) therapy with the BCR/ABL splicing patterns in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). Blood, 80, Suppl., 210a (abstract).
45. Shepherd, P., Suffolk, R., Halsey, J. & Allan, N. (1995) Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomised trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase or survival. Br J Haematol. 89, 546-554.
46. Lee, M.S., Kantarjian, H.M., Talpaz, M., Freireich, E.J., Deisseroth, A., Trujillo, J.M. & Stass, S.A. (1992) Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome positive chronic myelogenous leukemia following interferon therapy. Blood, 79, 1920-1923.
47. Malinge, M.C., Mahon, F.X., Delfeau, M.H., Daheron, L., Kitzis, A., Guilhot, F., Tanzer, J. & Grandchamp, B. (1992) Quantitative determination of the hybrid bcr-abl RNA in patients with chronic myelogenous leukemia under interferon therapy. Br J Haematol, 82, 701-707.
48. Hochhaus, A., Lin, F., Reiter, Skladny, H., van Rhee, F., Shepherd, P.C., Allan, N.C., Hehlmann, R., Goldman, J.M. & Cross, N.C. (1995) Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α. Br J Haematol, 91, 126-131.
49. Gaiger, A., Henn, T., Horth, E., Geissler, K., Mitterbauer, G., Maier-Dobersberger, T., Greinix, H., Mannhalter, C., Haas, O.A., Lechner, K. & Lion, T. (1995) Increase of bcr-abl chimeric mRNA expression in tumour cells of patients with chronic myeloid leukemia precedes disease progression. Blood, 86, 2371-2378.
50. Guilhot, F., & Lacotte-Thierry, L. (1998) Interferon-α: mechanism of action in chronic myelogenous leukemia in chronic phase. Hematol Cell Ther, 40, 237-239.
51. Giralt, S., Kantarjian, H. & Talpaz, M. (1995). The natural history of chronic myelogenous leukemia in the interferon era. Seminars in Hematology, 32, 152-158.
52. Santucci, M.A., Soligo, D., Pileri, S., Zuffa, E., Testoni, N. & Tura, S. (1993) Interferon-alpha effects on stromal compartment of normal and chronic myeloid leukemia hematopoiesis. Leukemia & Lymphoma, 1, Suppl., 1, 113-118.
53. Gordon, M.Y., Marley, S.B., Lewis, J.L., Davidson, R.J., Nguyen, D.,X., Grand, F.H., Amos, T.A. & Goldman, J.M. (1998) Treatment with interferon-α preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. J Clin Invest. 102, 710-715.
54. Cornelissen, J.J., Ploemacher, R.E., Wognum, B.W., Borsboom A, Kluin-Nelemans, H.C., Hagemeijer, A. & Lowenberg, B. (1998) An in vitro model for cytogenetic conversion in CML: interferon-α preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture. J Clin Invet, 102, 976-983.
55. Pendergast, A.M., Quilliam, L.A., Cripe, L.D., Bassing, C.H., Dai, Z., Li, N., Batzer, A., Rabun, K.M., Der. C.J., Schlessinger, J. & Gishizky, M.L. (1993) BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell, 75, 175-85.
56. Contente, S., Kenyon, K. Rimoldi, D. & Friedman, R.M. (1990) Expression of gene rrg is associated with reversion of NIH 3T3 transformed hy LTR-c-H-ras. Science, 249, 796-798.
57. Noda, M. (1993) Mechanisms of reversion [Review]. FASEB J, 7, 834-840.
58. Gutterman, J.U. (1994) Cytokine therapeutics: lessons from interferon-α. Proc Natl Acad Sci USA, 91, 1198-1205.
59. Bhatia, R., McCarthy, J.B., & Verfaillie, C.M. (1996) Interferon-α restores normal β1 intergrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood, 87, 3883-3891.
60. Upadhyaya, G., Guba, S.C., Sih, S.A., Feinberg, A.P., Talpaz, M., Kantarjian, H.M., Deisseroth, A.B. & Emerson, S.G. (1991) Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest, 88, 2131-2136.
61. Keating, A. (1993) Investigation of bcr-abl transcription by Ph-positive chronic myeloid leukemia progenitors. Stem Cells, 3, 31-33.
62. Oka, T., Sastry, K.J., Nehete, P., Schapiro, S.J., Guo, J.Q., Talpaz, M. & Arlinghaus, R.B. (1998) Evidence for specific immune response against p210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia, 12, 155-163.
63. Jiang, Y.Z., Kanfer, E.J., Macdonald, D., Cullis, J.O., Goldman, J.M. & Barrett, A.J. (1991) Graft-versus-leukemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. Bone Marrow Transplant, 8, 253-258.
64. Datta, A.R., Barrett, A.J., Jiang, Y.Z., Giumaraes, A., Mavroudis, D.A., van Rhee, F., Gordon, A.A. & Madrigal, A. (1994) Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: A model for separating GVHD from GVL reactions. Bone Marrow Transplant, 14, 517-524.
65. Fujii, S-I., Shimizu, K., Fujimoto, K., Kiyokawa, T., Shimomura, T., Taniguchi, O., Kinoshita, M. & Kawano, F. (1999) Analysis of a vaccinated chronic myelogenous leukemia patient with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn J Cancer Res, 90, 1117-1129.
66. Falkenburg, J.H.F., Goselink, H.M., van der Harst, D., van Luxemburg-Heijs, S.A.P., Kooy-Winkelaar, Y.M.C., Faber, L.M., de Kroon, J., Brand, A., Fibbe, W.E., Willemze, R. & Goulmy, E. (1991) Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med, 174, 27-33.
67. Tilkin, A.F., Lubin, R., Soussi, T., Lazar, V., Janin, N., Mathieu, M.C., Lefrere, I., Carlu, C., Roy, M., Kayibanda, M., Bellet, O., Guillet, J. & Paillerets, B.B. (1995) Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol, 25, 1765-1769.
68. Jung, S. & Schluesener, H. (1991) Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med, 173, 273-276.
69. McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K.M., Green, D.R. & Cotter, T.G. (1994) BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood, 83, 1179-87.
70. McWhirter, J.R. & Wang, J.Y. (1993) An actin-binding function contributes to transformation by the bcr-abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO Journal, 12, 1533-1546.
71. Calabretta, B., Venturelli, D., Kaczmarek, L., Narni, F., Talpaz, M., Anderson, B., Beran, M. & Baserga, R. (1986) Altered expression of G1-specific genes in human malignant myeloid cells. Proc Natl Acad Sci USA, 83, 1495-1498.
72. Lee, S.W., Tomasetto, C. & Sager, R. (1991) Positive selection of candidate tumor-suppressor genes by subtractive hybridization. Proc Natl Acad Sci USA, 88, 1825-1829.
73. Ten Bosch, G.J., Toornvliet, A.C., Friede, T., Melief, C.J. & Leeksma, O.C. (1995) Recognition of peptides corresponding to the joining region of p210 BCR-ABL protein by human T cells. Leukemia, 9, 1344-1348.
74. Pawelec, G., Max, H., Halder, T., Bruserud, O., Merl, A., de Silva, P. & Kalbacher, H. (1996) BCR/ABL leukemia onocogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low fequency in the repertoire of normal donors. Blood, 88, 2118-2124.
75. Chen, W., Peace, D.J., Rovira, D.K., You, S.G. & Cheever, M.A. (1992) T-cell immunity to the joining region of p210 BCR-ABL protein. Proc Natl Acad Sci USA, 89, 1468-1472.
76. Bocchia, M., Korontsvit, T., Xu, Q., Mackinnon S. Yang SY, Sette A, & Scheinberg DA. (1996) Specific human cellular immunity to bcr-abl onocogene-derived peptides. Blood, 87, 3587-3592.
77. + T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysate. Blood, 90, 290-297.
78. Bocchia, M., Wentworth, P.A., Southwood, S., Sidney, J., McGraw, K., Scheinberg, D.A. & Sette, A. (1995). Specificbinding of leukemia oncogene fusion protein peptides to HLA class 1 molecules. Blood, 85, 2680-2684.
79. + T lymphocytes recognize the fusion region of BCR-ABL hybrid protein present in chronic myelogenous leukemia. Blood, 86, Suppl., 158.
80. Greco, G., Fruci, D., Accapezzato, D., Barnaba, V., Nisini, R., Alimena, G., Montefusco, E., Vigneti, E., Butler, R., Tunigaki, N. & Tosi R. (1996) Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia, 10, 693-699.
81. Langlade-Demoyen, P., Abastado, J.P., Even, J., Gourru, G., Leblond, V., Binet, J.L. & Kourilsky, P. (1995) Cytotoxic T cell response against 210 kDA chimeric protein coded by the BCR-ABL fusion gene in chronic myeloid leukemia. Blood, 86, Suppl., 525.
82. +cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood, 92, 3355-3361.
83. Ten Bosch, G.J., Kessler, J.H., Joosten, A.M., Bres-Vloemans, A.A., Geluk, A., Godthelp, B.C., van Bergen, J., Melief, C.J. & Leeksma, O.C. (1999) A BCR-ABL oncoprotein p210 b2a2 fusion sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. Blood, 94, 1038-1045.
84. Jameson, S.C., Carbone, F.R. & Bevan, M.J. (1994) Clone specific T-cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells. J Exp Med. 177, 1541-1550.
85. Sloan-Lancaster, J. & Allen, P.M. (1996) Altered peptide ligand-induced partial T-cell activation: Molecular mechanisms and roles in T-cell biology. Ann Rev Immunol, 14, 1-27.
86. Janeway, C.A. & Travers, P. (1994) Immonobiology: The Immune System in Health and Disease. London, Current Biology.
87. Shlomchik, W.D. & Emerson, S.G. (1996) The immunobiology of T cell therapies for leukemias [Review]. Acta Haematol, 96, 189-213.
88. Paul, W.E. & Seder, R.A. (1994) Lymphocyte responses and cytokines. Cell, 76, 241-251.
89. Rudd, C.E., Janssen, O., Cai, Y.C., da Silva, A.J., Raab, M. & Prasad, K.V. (1994) Two-step TCR zeta/CD3-CD4 and CD28 signaling in T cells: SH2/SH3 domains, protein-tyrosine and lipid kinases. Immunology Today, 15, 225-234.
90. Weiss, A. (1993) T cell antigen receptor signal transduction: A tale of tails and cytoplasmic protein-tyrosine kinases [Review]. Cell, 73, 209-212.
91. Weiss, A. & Littman, D.R. (1994) Signal transduction by lymphocyte antigen receptors [Review]. Cell, 76, 263-274.
92. Guinan, E.C., Gribben, J.G., Boussiotis, V.A., Freeman, G.J. & Nadler, L.M. (1994) Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity [Review]. Blood 84, 3261-3238.
93. Willcox, B.E., Gao, G.F., Wyer, J.R., Ladbury, J.E., Bell, J.I., Jakobsen, B.K. & van der Merwe, P.A. (1999) TCR binding to peptide-MHC stabilizes a flexible recognition interface. Immunity 10, 357-365.
94. Guinan, E.C., Gribben, J.G., Boussiotis, V.A., Freeman, G.J., Nadler, L.M. & Thompson, C.B. (1994) The B7 and CD28 receptor families. [Review]. Immunology Today, 15, 321-331.
95. Boussiotis, V.A., Freeman, G.J., Grey, G., Gribben, J. & Nadler, L.M. (1993) B7 but not intracellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med, 178, 1753-1763.
96. Boussiotis, V.A., Gribben, J., Freeman, G.J. & Nadler, L.M. (1994) Blockade of the CD28 costimulatory pathway: A means to induce tolerance [Review]. Curr Opin Immunol, 6, 797-807.
97. Boussiotis, V.A., Barber, D.L., Nakarai, T., Freeman, G.J., Gribben, J.G., Bernstein, G.M., D'Andrea, A.D., Ritz, J. & Nadler, L.M. (1994) Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science, 266, 1039-1042.
98. Gimmi, C.D., Freeman, G.J., Gribben, J., Grey, G. & Nadler, L.M. (1993) Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA, 90, 6586-6590.
99. Maini, M.K., Casorati, G., Dellabona, P., Wack, A. & Beverley, P.C.L. (1999) T-cell clonality in immune responses. Immunology Today, 20, 262-266.
100. Piper, H., Litwin, S. & Mehr, R. (1999) Models for antigen receptor gene rearrangement. II. Multiple rearrangement in the TCR: Allelic exclusion or inclusion? J Immunol, 163, 1799-1808.
101. Savage, P.A., Boniface, J.J. & Davis, M.M. (1999) A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity, 10, 485-492.
102. Posnett, D.N., Sinha, R., Kabak, S. & Russo, C. (1994) Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy". J Exp Med, 179, 609-618.
103. Wack, A., Montagna, D., Dellabona, P. & Casorati, G. J. (1996) An improved PCR-heteroduplex method permits high-sensitivity detection of clonal expansions in complex T cell populations. J Immunol Methods, 196, 181-192.
104. +T cells in allogeneic bone marrow transplantation recipients. J Immunol, 157, 5739-5747.
105. Maryanski, J.L., Jongeneel, C.V., Bucher, P., Casanova, J.L. & Walker, P.R. (1996) Single-cell PCR analysis of TCR repertoires selected by antigen in vivo: a high magnitude CD8 response is comprised of very few clones. Immunity, 4, 47-55.
106. Cochet, M., Pannetier, C., Regnault, A., Darche, S., Leclerc, C. & Kourilsky, P. (1992) Molecular detection and in vivo analysis of the specific T cell response to a protein antigen. Eur J Immunol, 22, 2639-2647.
107. Mugnaini, E.N., Egeland, T., Syversen, A.M., Spurkland, A. & Brinchmann, J.E. (1999) Molecular analysis of the complementarity determining region 3 of the human T cell receptor beta chain. Establishment of a reference panel of CDR3 lengths from phytohaemagglutinin activated lymphocytes. J Immunol Methods, 223, 207-216.
108. + subsets. Int Immunol, 10, 1281-1288.
109. Wedderburn, L.R., Maini, M.K., Patel, A., Beverley, P.C.L. & Woo, P. (1999) Molecular fingerprinting reveals non-overlapping T cell oligoclonality between an inflamed site and peripheral blood. Int Immunol, 11, 535-543.
110. Yamamoto, K., Sakoda, H., Nakajima, T., Kato, T., Okubo, M., Dohi, M., Mizushima, Y., Ito, K., & Nishioka, K. (1992) Accumulation of multiple T cell clonotypes in the synovial lesions of patients with rheumatoid arthritis revealed by a novel clonality analysis. Int Immunol, 4, 1219-1223.
111. Kurokawa, M., Furukawa, H., Yabe, T., Mutsui, T., Toda, M., Hamada, C., Kasukawa, R., Yamamoto, K., Nishioka K. & Kato., T. (1999) Frequency of clonally expanded T cells evaluated by PCR from a single cell. J Immunol Methods, 224, 203-208.
112. + T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med, 187, 1395-1402.
113. +T cells in acute infectious mononucleosis. Nat Med, 2, 906-911.
114. + population. Immunology, 94, 529-35.
115. Algeciras, A., Dockrell, D.H., Lynch, D.H. & Paya, C.V. (1998) CD4 regulates susceptibility to Fas ligand-and tumor necrosis factor-mediated apoptosis. J Exp Med, 187, 711-20.
116. + memory T cells in virus-infected hosts. J Exp Med, 183, 1367-75.
117. Ehl, S., Hoffmann-Rohrer, U., Nagata, S., Hengartner, H. & Zinkernagel, R. (1996) Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J Immunol, 156, 2357-60.
118. Singer, G.G. & Abbas, A.K. (1994) The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity, 1, 365-71.
119. Sytwu, H.K., Liblau, R.S. & McDevitt, H.O. (1996) The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity, 5, 17-30.
120. + T cells. Immunity, 7, 885-95.
121. + cells become refractory to interleukin 2. J Exp Med., 163, 270-84.
122. Vella, A.T., Dow, S., Potter, T.A., Kappler, J. & Marrack, P. (1998) Cytokine induced survival of activated T cells in vitro and in vivo. Proc Natl Acad Sci USA, 95, 3810-3815.
123. + T cells in vivo by IL-15. Immunity, 8, 591-599.
124. Zeng, W., Nakao, S., Takamatsu, H., Yachie, A., Takami, A., Kondo, Y., Sugimori, N., Yamazaki, H., Miura, Y., Shiobara, S., & Matsuda, T. (1999) Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Blood, 93, 3008-3016.
125. Coleman, S., Perera, P., Fisher, J., Hoy, T., Burnett, A.K. & Lim, S.H. (1995). Abnormal TCR V beta repertoire in patients with chronic myeloid leukaemia. Br J Haematol, 90, 358-363.
126. Shimomura, T., Fujii, S-I., Ezaki, I., Osato, M., Fujimoto, K., Takatsuki, K., Yamamoto, K. & Kawakita, M. (1999) Characeterization of T-cell receptor β chain mRNA expression in IFN-α-responsive chronic myelogenous leukaemia patients. Br J Haematol, 105, 173-180.
127. Rezvany, M.R., Jeddi-Tehrani, M., Osterborg, A., Kimby, E., Wigzell, H. & Mellstedt, H. (1999) Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood 94, 1063-1069.
128. Trentin, L., Imberti, L., Zambello, R., Sottini, A., Raimondi, R., Facco, M., Cazzavillan, S., Bonoldi, E., Signorini, S., Bacigalupo, A., Semenzato, G., Rodeghiero, F. & Primi, D. (1999) Detection of identical T-cell clono-type expansions in both the donor and recipient after allogeneic bone marrow transplantation. Br J Haematol., 106, 119-127.
129. Claret, E.J., Alyea, E.P., Orsini, E., Pickett, C.C., Collins, H., Wang, Y., Neuberg, D., Soiffer, R.J. & Ritz, J. (1997) Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymhpocyte infusion. J Clin Invet, 4, 855-866.
130. Cortes, J., Fayad, L., Kantarjian, H., O'brien, S., Lee, M-S. & Talpaz, M. (1998) Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogeneous leukemia. Leukemia 12, 455-462.
131. Mahon, F.X., Faberes, C., Pueyo, S., Cony-Makhoul, P., Salmi, R., Boiron, J.N., Marit, G., Bilhou-Nabera, C., Carrere, A., Montastruc, M., Pigneux, A., Bernard, P.H. & Reiffers, J. (1998) Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interteron-α. Blood, 92, 4059-4065.
132. Choudhury, A., Toubert, A., Douay, C., Charron, D., Champlin, R. & Claxton, D (1997). MHC restriction and preferential TCR Vβ usage in anti-leukemic T lymphocytes elicited against autologous, CML-derived dendric cells from different CML patients. Blood, 90, (Suppl. 1), 198.
133. Molldrem, J.J., Lee, P.P., Wang, C., Champlin, R.E. & Davis, M.M. (1999) A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res, 59, 2675-2681.
134. Falkenburg, J.H.F., Wafelman, A.R., Joosten, P., Smit, W.M., van Bergen, C.A.M., Bongaerts, R., Lurvink, E., van der Hoorn, M., Kluck, P., Landegent, J.E., Kluin-Nelemans, H.C., Fibbe, W.E. & Willemze, R. (1999) Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood, 94, 1201-1208.
135. + cord blood cell-derived and irradiated tumor cell-primed dendritic cells. Int J Hematol, 68, 169-182.
136. + hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogeneous leukemia patients. Cancer Res, 59, 2150-2158.
137. Fujii, S-I., Hamada, H., Fujimoto, K., Shimomura, T. & Kawakita, M. (1999) Activated dendritic cells from bone marrow cells receiving cytokine-expressing tumor cells are associated with the enhanced survival of mice bearing synegenic tumors. Blood, 93, 1-9.
138. +T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood, 91, 977-983.